World Drug Sales During January-November 1996

10 February 1997

World sales of medical products through retail pharmacy outletsincreased 7% to $130.11 billion in the world's 10 leading pharmaceutical markets during January-November 1996, reports IMS International.

The most significant factor during the period was the 11% growth reported for the US market, which advanced to $54.05 billion from $48.90 billion in the like, year-earlier period. The largest growth during January-November 1996 was in fact reported for Italy, rising 12% to $8.21 billion, and the third largest was in the UK, up 10% to $6.17 billion.

Sales on the Spanish market were up 9% to $4.70 billion, while in Germany, the largest single European market, they advanced 7% to $15.29 billion, and the Belgian market was up 6% to $1.82 billion. Canada advanced 4% to $3.42 billion, while turnover in France increased 2% to $13.56 billion and Japanese sales rose 2% to $21.07 billion. The Dutch market was flat at $1.80 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight